Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus.
Publication
, Journal Article
Ghoreifi, A; Abern, M
Published in: Urol Oncol
March 2025
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Urol Oncol
DOI
EISSN
1873-2496
Publication Date
March 2025
Volume
43
Issue
3
Start / End Page
186 / 187
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Ghoreifi, A., & Abern, M. (2025). Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus. Urol Oncol, 43(3), 186–187. https://doi.org/10.1016/j.urolonc.2024.11.027
Ghoreifi, Alireza, and Michael Abern. “Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus.” Urol Oncol 43, no. 3 (March 2025): 186–87. https://doi.org/10.1016/j.urolonc.2024.11.027.
Ghoreifi A, Abern M. Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus. Urol Oncol. 2025 Mar;43(3):186–7.
Ghoreifi, Alireza, and Michael Abern. “Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus.” Urol Oncol, vol. 43, no. 3, Mar. 2025, pp. 186–87. Pubmed, doi:10.1016/j.urolonc.2024.11.027.
Ghoreifi A, Abern M. Re: Hera et al. impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombus. Urol Oncol. 2025 Mar;43(3):186–187.
Published In
Urol Oncol
DOI
EISSN
1873-2496
Publication Date
March 2025
Volume
43
Issue
3
Start / End Page
186 / 187
Location
United States
Related Subject Headings
- Urology & Nephrology
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis